Compare Stocks → Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (From Paradigm Press) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:CYTRNASDAQ:ENTXNASDAQ:LIFENASDAQ:OTLK Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYTRLadRx$0.09$0.05▼$0.86$4.14MN/A99,706 shs4,000 shsENTXEntera Bio$2.22+8.3%$1.60$0.52▼$3.35$63.94M1.7210,937 shs113,415 shsLIFEaTyr Pharma$1.62-1.2%$1.83$1.08▼$2.70$110.06M1.25508,302 shs238,256 shsOTLKOutlook Therapeutics$8.20+1.4%$8.59$4.00▼$40.60$106.68M0.04537,698 shs151,652 shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYTRLadRx0.00%0.00%0.00%0.00%0.00%ENTXEntera Bio+3.02%-18.65%+29.75%+133.03%+148.18%LIFEaTyr Pharma+2.50%-3.53%-15.90%+6.49%-12.53%OTLKOutlook Therapeutics-0.98%-6.15%-6.26%-8.86%-65.43%SHOCKING Crypto Leak… (Ad)A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCYTRLadRxN/AN/AN/AN/AN/AN/AN/AN/AENTXEntera Bio1.6111 of 5 stars3.53.00.00.03.30.00.0LIFEaTyr Pharma2.0463 of 5 stars3.43.00.00.03.21.70.0OTLKOutlook Therapeutics3.0715 of 5 stars4.42.00.00.02.81.70.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCYTRLadRxN/AN/AN/AN/AENTXEntera Bio3.00Buy$10.00350.45% UpsideLIFEaTyr Pharma2.75Moderate Buy$23.671,360.91% UpsideOTLKOutlook Therapeutics2.88Moderate Buy$46.43466.16% UpsideCurrent Analyst RatingsLatest OTLK, LIFE, ENTX, and CYTR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/2/2024ENTXEntera BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.003/27/2024OTLKOutlook TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$50.003/25/2024OTLKOutlook TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$30.003/15/2024LIFEaTyr PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$35.003/15/2024LIFEaTyr PharmaRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$19.00 ➝ $16.002/21/2024LIFEaTyr PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$35.002/16/2024OTLKOutlook TherapeuticsCapital One FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight2/15/2024OTLKOutlook TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$60.001/25/2024OTLKOutlook TherapeuticsBrookline Capital ManagementSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$31.401/25/2024OTLKOutlook TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$40.00(Data available from 4/23/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCYTRLadRxN/AN/AN/AN/AN/AN/AENTXEntera Bio$130K491.82N/AN/A$0.36 per share6.17LIFEaTyr Pharma$350K314.47N/AN/A$1.54 per share1.05OTLKOutlook TherapeuticsN/AN/AN/AN/A($1.11) per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCYTRLadRxN/AN/A0.00N/AN/AN/AN/AN/AN/AENTXEntera Bio-$8.89M-$0.31N/AN/AN/AN/A-101.78%-83.90%5/3/2024 (Estimated)LIFEaTyr Pharma-$50.39M-$0.96N/AN/AN/AN/A-49.84%-39.12%5/14/2024 (Estimated)OTLKOutlook Therapeutics-$58.98M-$4.00N/AN/AN/AN/A-3,741.39%-132.37%5/20/2024 (Estimated)Latest OTLK, LIFE, ENTX, and CYTR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/14/2024Q4 2023LIFEaTyr Pharma-$0.23-$0.25-$0.02-$0.25N/AN/A3/8/2024Q4 2023ENTXEntera Bio-$0.08-$0.07+$0.01-$0.07N/AN/A2/14/2024Q1 2024OTLKOutlook Therapeutics-$1.00-$0.80+$0.20-$0.04N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCYTRLadRxN/AN/AN/AN/AN/AENTXEntera BioN/AN/AN/AN/AN/ALIFEaTyr PharmaN/AN/AN/AN/AN/AOTLKOutlook TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCYTRLadRxN/AN/AN/AENTXEntera BioN/A10.3210.32LIFEaTyr Pharma0.026.276.27OTLKOutlook TherapeuticsN/A0.440.44OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCYTRLadRxN/AENTXEntera Bio14.11%LIFEaTyr Pharma61.72%OTLKOutlook Therapeutics11.20%Insider OwnershipCompanyInsider OwnershipCYTRLadRxN/AENTXEntera Bio8.90%LIFEaTyr Pharma3.70%OTLKOutlook Therapeutics5.30%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCYTRLadRxN/A45.04 millionN/ANot OptionableENTXEntera Bio1728.80 million26.24 millionOptionableLIFEaTyr Pharma5667.94 million65.43 millionOptionableOTLKOutlook Therapeutics2413.01 million12.32 millionOptionableOTLK, LIFE, ENTX, and CYTR HeadlinesSourceHeadlineBest's Market Segment Report: AM Best Revises Outlook on London Market Insurance Segment to Positivefinance.yahoo.com - April 22 at 1:21 PMUSD/JPY Forecast: BoJ’s Rate Hike Talks and the Yen’s Outlookfxempire.com - April 22 at 1:21 PMWGA Releases New Housing Finance Outlookmarkets.businessinsider.com - April 22 at 1:21 PMOutlook Money’s Tushar Ghosh elevated to Publishing Directorpitchonnet.com - April 22 at 1:21 PMOutlook: How to set up breaks between your meetingsmsn.com - April 22 at 1:21 PMOutlook Therapeutics, Inc. (OTLK)finance.yahoo.com - April 21 at 8:02 PMWorld Economic Outlook: IMF revises GDP predictions for LATAM and the Carribbeaninvezz.com - April 18 at 6:25 PMWorld Polyethylene High Density (HDPE) Market Outlook 2024-2033: Capacities, Production, Consumption, Trade Statistics, and Pricesfinance.yahoo.com - April 18 at 6:25 PMEconomic Outlook 2024 in Springfieldconnectionnewspapers.com - April 18 at 6:25 PMBosch Flags Further Cost Cuts After Giving 'Subdued' Outlook for 2024usnews.com - April 18 at 6:25 PMReporter's Guarentee | Outlook's Rakhi Bose In Conversation With Dalit Villagers In Saharanpur Districtoutlookindia.com - April 18 at 6:25 PMOutlook Therapeutics® Announces Closing of Private Placement of $5.0 Millionglobenewswire.com - April 15 at 4:15 PMBiotech on a Budget: 7 Stocks Under $10 With Huge Potentialinvestorplace.com - April 15 at 12:54 PMOutlook Therapeutics (NASDAQ:OTLK) versus Vigil Neuroscience (NASDAQ:VIGL) Head-To-Head Contrastamericanbankingnews.com - April 15 at 1:14 AMUS Consumer Sentiment Falls Slightly as Outlook for Inflation Worsensmsn.com - April 14 at 9:03 AMMicrosoft Outlook 2010's Default Profile Pic Was Based on Bill Gates' 1977 Mug Shot?msn.com - April 14 at 9:03 AMOutlook Therapeutics, Inc. (NASDAQ:OTLK) Receives Consensus Recommendation of "Moderate Buy" from Analystsamericanbankingnews.com - April 13 at 4:32 AMFed's Williams: Outlook is uncertain, Fed must be data-dependentfxstreet.com - April 11 at 6:05 PMNational Gas’ Summer Outlook 2024: Stable supply, reduced exportsenergylivenews.com - April 11 at 6:05 PMADB Outlook forecasts 7 % GDP growth in 2025bbs.bt - April 11 at 6:05 PMNatural Gas Price Forecast: Moving Average Breakout Improves Bullish Outlookfxempire.com - April 11 at 1:44 AMStock Market Today: Wall Street Falls After Hot Inflation Data Burns Hopes for a June Rate Cutmsn.com - April 11 at 1:44 AMBitdefender now has identity protection for Gmail and Outlookmsn.com - April 11 at 1:44 AMInsiders are Piling into These 10 Healthcare Stocks in 2024finance.yahoo.com - April 10 at 3:44 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Value Stocks Too Small For Buffett’s PortfolioMarch 28, 2024 12:16 PMView 3 Value Stocks Too Small For Buffett’s PortfolioFoot Locker Builds Up Another Head of Steam; Gains ImminentMarch 28, 2024 10:58 AMView Foot Locker Builds Up Another Head of Steam; Gains Imminent5 Stocks in the Current Bull Market with Upside to ComeApril 5, 2024 10:14 AMView 5 Stocks in the Current Bull Market with Upside to Come5 Top-Rated Dividend Stocks With Double-Digit UpsideMarch 25, 2024 11:19 AMView 5 Top-Rated Dividend Stocks With Double-Digit UpsideBlackstone’s $10 Billion Bet on Property Prices Going UpApril 11, 2024 7:30 AMView Blackstone’s $10 Billion Bet on Property Prices Going UpAll Headlines Company DescriptionsLadRxNASDAQ:CYTRLadRx Corp. is a biopharmaceutical research and development company, which engages in the discovery, research, and clinical development of novel anti-cancer drug candidates. It focuses on developing the Linker Activated Drug Release (LADR) technology platform, a discovery engine to help create a pipeline of anti-cancer molecules that will avoid unacceptable systemic toxicity while delivering highly potent agents directly to the tumor. The company was founded in 1985 and is headquartered in Los Angeles, CA.Entera BioNASDAQ:ENTXEntera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and hGh for the GH deficiency. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.aTyr PharmaNASDAQ:LIFEaTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.Outlook TherapeuticsNASDAQ:OTLKOutlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.